MX9305016A - Metodo para inhibir la replicacion hiv utilizando il-4. - Google Patents

Metodo para inhibir la replicacion hiv utilizando il-4.

Info

Publication number
MX9305016A
MX9305016A MX9305016A MX9305016A MX9305016A MX 9305016 A MX9305016 A MX 9305016A MX 9305016 A MX9305016 A MX 9305016A MX 9305016 A MX9305016 A MX 9305016A MX 9305016 A MX9305016 A MX 9305016A
Authority
MX
Mexico
Prior art keywords
hiv replication
inhibiting hiv
hiv
patient
inhibiting
Prior art date
Application number
MX9305016A
Other languages
English (en)
Spanish (es)
Inventor
Jerome Schwarts
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of MX9305016A publication Critical patent/MX9305016A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
MX9305016A 1992-08-19 1993-08-18 Metodo para inhibir la replicacion hiv utilizando il-4. MX9305016A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US93213492A 1992-08-19 1992-08-19

Publications (1)

Publication Number Publication Date
MX9305016A true MX9305016A (es) 1994-02-28

Family

ID=25461831

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9305016A MX9305016A (es) 1992-08-19 1993-08-18 Metodo para inhibir la replicacion hiv utilizando il-4.

Country Status (22)

Country Link
US (1) US5700461A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0656785B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP2711182B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR950702838A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1086437A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE163860T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU683427B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2142862C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CZ (1) CZ38095A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE69317428T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2113549T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI950696L (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HUT72709A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL106717A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX9305016A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO950599L (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ255735A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL307508A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SK (1) SK21295A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TW291439B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO1994004179A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA936018B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE262920T1 (de) 1995-11-02 2004-04-15 Schering Corp Kontinuierliche, niedrigdosierte zytokine- infusionstherapie
US20050124645A1 (en) * 1998-04-20 2005-06-09 Finkel Terri H. Methods and compositions for increasing CD4lymphocyte immune responsiveness
US20030232738A1 (en) * 1998-04-20 2003-12-18 National Jewish Medical And Research Center Method and composition for increasing CD4+ T lymphocyte immune responsiveness
US20040132161A1 (en) * 1998-04-20 2004-07-08 Finkel Terri H. Methods and compositions for increasing CD4lymphocyte immune responsiveness
BR9911457A (pt) * 1998-06-24 2001-12-11 Univ Emory Uso de 3'-azida-2', 3'-dideoxiuridina em combinaçãocom drogas anti-hiv adicionais para a manufaturade um medicamento para o tratamento de hiv
US6734192B1 (en) * 1999-08-23 2004-05-11 Mp-1 Inc. Treatment of viral infections

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4724232A (en) * 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
JPH02485A (ja) * 1987-08-03 1990-01-05 Yuu Honshiyo 新規なヒトインターロイキン４、該因子を発現させるための組換えベクター及びそのベクターにより形質転換された形質転換体
US5011829A (en) * 1989-06-02 1991-04-30 G. D. Searle & Co. Pharmaceutical composition and method of inhibiting virus
ATE133074T1 (de) * 1990-03-21 1996-02-15 Schering Corp Verwendung von il-4 zur verstärkung der immunantwort auf infektiöse antigen- herausforderungen
US5206345A (en) * 1990-08-02 1993-04-27 Fred Hutchinson Cancer Research Center Il-4 and tnf induce mab 6g10-recognized expression on bone marrow stromal cells
EP0490006B1 (en) * 1990-12-13 1994-06-22 Schering-Plough Pharmaceutical compositions for the treatment of B-cell malignancies

Also Published As

Publication number Publication date
WO1994004179A1 (en) 1994-03-03
ES2113549T3 (es) 1998-05-01
NO950599D0 (no) 1995-02-17
FI950696A7 (fi) 1995-02-16
US5700461A (en) 1997-12-23
IL106717A0 (en) 1993-12-08
NZ255735A (en) 1997-06-24
JP2711182B2 (ja) 1998-02-10
NO950599L (no) 1995-02-17
CZ38095A3 (en) 1995-12-13
SK21295A3 (en) 1997-01-08
CA2142862C (en) 2000-05-30
EP0656785A1 (en) 1995-06-14
FI950696A0 (fi) 1995-02-16
AU5007593A (en) 1994-03-15
CA2142862A1 (en) 1994-03-03
TW291439B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1996-11-21
HU9500487D0 (en) 1995-04-28
ZA936018B (en) 1994-06-13
PL307508A1 (en) 1995-05-29
FI950696L (fi) 1995-02-16
DE69317428D1 (de) 1998-04-16
CN1086437A (zh) 1994-05-11
HUT72709A (en) 1996-05-28
EP0656785B1 (en) 1998-03-11
KR950702838A (ko) 1995-08-23
DE69317428T2 (de) 1998-07-02
JPH07506116A (ja) 1995-07-06
ATE163860T1 (de) 1998-03-15
AU683427B2 (en) 1997-11-13

Similar Documents

Publication Publication Date Title
NO944997D0 (no) Trombin-blodfraksjon for anvendelse ved en medisinsk fremgangsmåte
ES2125233T3 (es) Tratamiento de las infecciones retrovirales humanas con 2',3'-didesoxiinosina.
AR013742A1 (es) Metodo para el tratamiento de la hipercolesterolemia con polidialilamina no substituida
DK0607128T4 (da) Lægemiddel samt fremstilling deraf og anvendelse deraf ved bekæmpelsen af smerter og/eller betændelser hos dyr og mennesker
GB9523833D0 (en) Medical treatment
NO983008L (no) Kasserbar absorberende gjenstand
ES547738A0 (es) Un procedimiento para la preparacion de una composicion terapeutica que contiene un fosfato de dialquilo.
ES2081857T3 (es) Nuevos inhibidores de alpha-glucosidasa.
PT88151A (pt) Low pressure hydrogen peroxide vapor sterilization system
FI884643L (fi) Kertakäyttöisiä, imukykyisiä tuotteita pidätyskyvyttömille henkilöille
MX9300766A (es) Piridonas sustituidas por sulfonilbencilo, procedimiento para su obtencion y medicamentos que las contienen.
CO4950529A1 (es) Dihidropirimidinas y productos que las contienen
ES2057124T3 (es) Producto terapeutico para el tratamiento de estados peri- o post-menopausicos.
FI962445A7 (fi) Paroksetiinitabletteja ja menetelmä niiden valmistamiseksi
GR3015513T3 (en) Use of baclofen for the preparation of medicaments for the treatment of angina pectoris.
ES2061688T3 (es) Composiciones farmaceuticas que comprenden una calcitonina y un glicirricinato como mejorador de la absorcion.
ES2138603T3 (es) Procedimiento para el aislamiento de los factores ix, x y ii altamente purificados a partir del complejo protrombinico o del plasma humano.
ES2038650T3 (es) Procedimiento para preparar una composicion farmaceutica que comprende 3'-desoxitimidin-2'-eno-(3'-desoxi-2',3'-dideshidrotimidina) para tratar pacientes infectados con retrovirus.
AU6337886A (en) Glutamine treatment of catabolic dysfunction
MX9305016A (es) Metodo para inhibir la replicacion hiv utilizando il-4.
AU1866888A (en) Pharmaceutical dosage unit containing 17beta-oestradiol and desogestrel
ES554061A0 (es) Un procedimiento para la preparacion de una composicion farmaceutica que contiene como ingrediente activo una nueva a -butirolactma
ES2175153T3 (es) Uso de inhibidores de colinesterasa para la fabricacion de un medicamento para el tratamiento de la xerostomia.
ES2111013T3 (es) Una composicion profilactica/terapeutica que contiene ws7622a para evitar o tratar la coagulacion intravascular diseminada, la enfermedad infecciosa cronica del tracto respiratorio o la bronquitis cronica.
MX9206135A (es) Metodos